Kenneth L. van Golen

Kenneth L. van Golen

Auto-generated profile, based on publicly available information

Kenneth L. van Golen

Department of Internal Medicine, Division of Hematology and Oncology, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002
Verified
Journal Article
Closed access
QPQuintin Pan
Quintin Pan
CKCelina G. Kleer
Celina G. Kleer
KGKenneth L Van Golen
Kenneth L Van Golen
JIJennifer Irani
Jennifer Irani
KBKristen M Bottema
Kristen M Bottema
SMSofia D Merajver
Sofia D Merajver

21 June 2005 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MLMin Lin
Min Lin
MDMelinda M DiVito
Melinda M DiVito
SMSofia Merajver
Sofia Merajver
MBMadanamohan Boyanapalli
Madanamohan Boyanapalli
KGKenneth L van Golen
Kenneth L van Golen
Background: In the current study we investigated the role of caveolin-1 (cav-1) in pancreatic adenocarcinoma (PC) cell migration and invasion; initial steps in metastasis. Cav-1 is the major structural protein in caveolae; small Ω-shaped invaginations within the plasma membrane. Caveolae are involved in signal transduction, wherein cav-1 acts as a scaffolding protein to organize multiple molecular complexes regulating a variety of cellular events. Recent evidence suggests a role for cav-1 in promoting cancer cell migration, invasion and metastasis; however, the molecular mechanisms have not been described. The small monomeric GTPases are among several molecules which associate with cav-1. Classically, the Rho GTPases control actin cytoskeletal reorganization during cell migration and invasion. RhoC GTPase is overexpressed in aggressive cancers that metastasize and is the predominant GTPase in PC. Like several GTPases, RhoC contains a putative cav-1 binding motif. Results: Analysis of 10 PC cell lines revealed high levels of cav-1 expression in lines derived from primary tumors and low expression in those derived from metastases. Comparison of the BxPC-3 (derived from a primary tumor) and HPAF-II (derived from a metastasis) demonstrates a reciprocal relationship between cav-1 expression and p42/p44 Erk activation with PC cell migration, invasion, RhoC GTPase and p38 MAPK activation. Furthermore, inhibition of RhoC or p38 activity in HPAF-II cells leads to partial restoration of cav-1 expression. Conclusion: Cav-1 expression inhibits RhoC GTPase activation and subsequent activation of the p38 MAPK pathway in primary PC cells thus restricting migration and invasion. In contrast, loss of cav-1 expression leads to RhoC-mediated migration and invasion in metastatic PC cells.

28 November 2005 in Oncogene
Verified
Journal Article
Closed access
HYH Yao
H Yao
EDE J Dashner
E J Dashner
CGC M van Golen
C M van Golen
KGK L van Golen
K L van Golen

1 January 2002 in Neoplasia
Verified
Journal Article
Open access
KGKenneth L. van Golen
Kenneth L. van Golen
LBLiWei Bao
LiWei Bao
GBGeorge J. Brewert
George J. Brewert
KPKenneth J. Pienta
Kenneth J. Pienta
JKJeffrey M. Kamradt
Jeffrey M. Kamradt
SMSofia D. Merajver
Sofia D. Merajver
Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH(2) peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with intravenous Ac-PHSCN-NH(2) peptide survived tumor-free for more than 30 weeks post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH(2) peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.

1 June 2002
Verified
Journal Article
Closed access
KGKenneth L Van Golen
Kenneth L Van Golen
LBLiwei Bao
Liwei Bao
MDMelinda M DiVito
Melinda M DiVito
ZWZhifen Wu
Zhifen Wu
GPGeorge C Prendergast
George C Prendergast
SMSofia D Merajver
Sofia D Merajver

1 June 2003 in Breast Cancer Research
Verified
Journal Article
Open access
KGKenneth L van Golen
Kenneth L van Golen
A variety of phenotypic characteristics are required for a cancer cell to successfully complete the metastatic cascade. Acquisition of a motile and invasive phenotype is one requirement for a cell to become metastatically competent. The Rho (Ras homology) GTPases are a subfamily of small GTP-binding proteins, which are related to the Ras oncogene. All aspects of cellular motility and invasion are controlled by the Rho GTPases and are closely linked to signals from the extracellular environment, particularly in response to growth factors. Dysregulation of Rho activation through aberrant growth-factor signaling, loss of function of key Rho-regulatory proteins or overexpression of Rho mRNA could result in increased Rho activity and cellular motility. Therefore, the importance of the Rho GTPases in the progression of aggressive cancers, is becoming more appreciated.